Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

NCT05401097 is registered in ClinicalTrials.gov with Alice Mims as lead sponsor.

NCT NCT05401097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05401097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Lead sponsor
Alice Mims
Phase
Phase 2
Overall status
Recruiting
Start date
September 13, 2022
Completion date
June 30, 2029
Enrollment
125 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia